Tovinontrine

DB16193InvestigationalSmall molecule

Tovinontrine is an orally administered, highly selective phosphodiesterase 9 (PDE9) small molecule inhibitor. Tovinontrine is under investigation in clinical trial NCT04474314 (A Study of IMR-687 in Subjects With Sickle Cell...

Mechanism: Pharmacologically active on High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A
Curator reviewed
Formula / weight: C₂₁H₂₆N₆O₂ · 394.479 g/mol (avg)
Also known as: 6-((3S,4S)-4-METHYL-1-(2-PYRIMIDINYLMETHYL)-3-PYRROLIDINYL)-3-(TETRAHYDRO-2H-PYRAN-4-YL)IMIDAZO(1,5-A)PYRAZIN-8(7H)-ONE · 6-[(3S,4S-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imadazo[1,5-a]pyrazin-8-one · 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3- tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one · IMIDAZO(1,5-A)PYRAZIN-8(7H)-ONE, 6-((3S,4S)-4-METHYL-1-(2-PYRIMIDINYLMETHYL)-3-PYRROLIDINYL)-3-(TETRAHYDRO-2H-PYRAN-4-YL)-
Code names: AF-68722 · CK-1598 · IMR-687

Resolves to

Compound

UNIIW248Y1AKORCAS2062661-53-2ChEMBLCHEMBL4297290

Structure

InChIKeyGWGNPYYVGANHRJ-GDBMZVCRSA-NSMILESC[C@@H]1CN(CC2=NC=CC=N2)C[C@H]1C1=CN2C(=NC=C2C(=O)N1)C1CCOCC1

Targets

O76083PDE9A

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tovinontrine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account